News & Updates

Show Multimedia Only

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

In the first years of use, conjugated estrogens/bazedoxifene (CE/BZA) appears to be associated with slightly higher rates of endometrial cancer and endometrial hyperplasia compared with estrogen/progestin (EP) combination hormone therapy, according to a study.

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

20 Jul 2023 by

Among patients with treatment-naïve autoimmune hepatitis, more of those who receive mycophenolate mofetil achieve remission than those who receive azathioprine, as shown in the results of the CAMARO trial.

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

20 Jul 2023

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023 by

The addition of simvastatin to a nonselective beta blocker results in better survival among cirrhotic patients with variceal bleeding, reports a study presented at EASL 2023.

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Treatment with tirzepatide is associated with better lipid profile and waist circumference outcomes compared with placebo and other glucose-lowering drugs, according to a study.

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 by

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Baseline glycated haemoglobin (HbA1c) is the most robust risk factor for metformin failure, reveals a study, noting that routinely available clinical data may be used to identify high-risk patients who may benefit from closer monitoring and earlier treatment intensification.

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Which factors promote inappropriate prescribing among older patients in primary care?

19 Jul 2023 by

Several factors contribute to potentially inappropriate prescribing (PIP) among older persons in primary care settings, and these elements can be classified into patient, physician, and system, according to a Singapore study. These factors can help in designing complex interventions for PIP and in developing risk prediction tools to identify groups who may need further PIP-related interventions.

Which factors promote inappropriate prescribing among older patients in primary care?

19 Jul 2023

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

19 Jul 2023

Brolucizumab helps improve visual and anatomic outcomes in diabetic macular edema (DME), with long-term efficacy and durability and no new safety signals, as shown in the 100-week data from the phase III KESTREL and KITE studies.

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

19 Jul 2023

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

A new lotion formulation of 20% oxybutynin hydrochloride (20% OL) demonstrates efficacy in reducing palmar sweat volume among patients with primary palmar hyperhidrosis (PPHH) when compared with placebo, results of a phase III study have shown.

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

18 Jul 2023 by

Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

18 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Baseline HbA1c strongly predicts metformin failure

Baseline HbA1c strongly predicts metformin failure

Which factors promote inappropriate prescribing among older patients in primary care?

Which factors promote inappropriate prescribing among older patients in primary care?

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

Novel lotion formulation helps reduce palm sweating

Novel lotion formulation helps reduce palm sweating

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes